Patrick Campbell

Announced on August 24, rivaroxaban (Xarelto) has received its ninth indication from the US FDA. This time, the FDA has approved a label expansion to include patients with symptomatic peripheral artery disease who have undergone lower extremity revascularization.

With approval of the Evolut FX TAVR System announced on August 24, the Evolut TAVR Platform is now indicated for symptomatic severe aortic stenosis across all patient risk categories.

A new meta-analysis by investigators from Johns Hopkins details the prevalence of UACR testing in patient populations at increased risk of albuminuria, suggesting less than 40% of patients with diabetes underwent UACR testing and this figure dropped to less than 5% among patients with hypertension.

A review article details the prevalence and impact of sleep disorders in patients with type 2 diabetes as well as providing an overview current treatment options and research needs.

The approval of empagliflozin for reducing risk of CV death and hospitalization for heart failure in patients with HFrEF comes less than a year after results of EMPEROR-Reduced were presented at ESC 2020.

An analysis of registry data from more than 2.4 million births in Denmark suggests those born to mothers with diabetes were 39% more likely to experience high refractive error before turning 25 years old.

The latest scientific statement from the American Heart Association seeks to outline the cardiovascular risks associated with OSA or sleep-disordered breathing in children and adolescents while also providing insight into symptoms and risk factors for developing OSA or sleep-disordered breathing.

A recent analysis of health care spending data suggests nearly 1-in-6 heart failure patients forgo or delay care, while also suggesting delaying care ultimately increased healthcare spending by more than $8,000.

A recent study published in JAMA details increasing rates of gestational diabetes among first-time mothers in the US from 2011-2019, with rates increasing across all racial/ethnic subgroups examined in the 12 million person analysis.

A substudy of a prospective observational study performed at a hospital in Italy details potential associations of vitamin D levels with BMI and blood glucose and severity of COVID-19.

Eli Lilly and Company announced the FDA has expanded the label of insulin lispro-aabc injection (Lyumjev) to allow for administration via insulin pumps.

Using propensity score-matching, a new study is providing insight into the risk reduction and bleeding risk associated with various DOACs versus warfarin and one another in patients with nonvalvular atrial fibrillation and an increased gastrointestinal bleeding risk.

An analysis of data from a national health database in South Korea suggests increased BMI variability was linked to a 66% greater risk of mortality and a 19% greater risk of heart attack and stroke in patients with chronic kidney disease.

An analysis of more than 50,000 patients with chronic kidney disease indicates increased BMI variability was tied to increased risk of mortality, need for kidney replacement therapy, and cardiovascular disease events.

An analysis of data from a prospective cohort study of more than 50k suggests increased intake of vitamin K could lower a person's risk of ASCVD hospitalization by more than 20%.

An analysis of patients from a hospital in Belgium provides insight into the impact of COVID-19 and lockdowns on weight loss and overall health on patients who underwent gastric bypass and were impacted by COVID-19 during their first postoperative year.

Data from a major registry suggests more than 90% of patients with heart failure with reduced ejection were discharged from the hospital without being prescribed sacubitril/valsartan (Entresto) and more than 90% of those patients never filled a prescription in the year following hospitalization.

An analysis of the NCDR LAAO Registry suggests women had longer hospital stays and a greater risk of adverse events following implant of the Watchman device than their male counterparts.

An analysis of the ARIC study suggests patients with diabetes had a 67% greater risk of hospitalization for infection than their counterparts without diabetes.

The latest recommendation statement reaffirms the USPSTF's 2014 guidance, which included a B recommendation for screening for gestational diabetes at 24 weeks of gestation or after.

A clinical pharmacist and nurse practitioner offer perspective on how the interchangeable biosimilar approval of Semglee impacts discussions around the cost of insulin for patients with diabetes and what they think is important for patients, providers, and pharmacists to know about the historic FDA approval.

Titled, "Insulin for All? How Recent Developments Impact Insulin Affordability," this 3-part video series from Diana Isaacs, PharmD, and Lucia Novak, CRNP, explores how news from Walmart and Novo Nordisk and a historic approval from the US FDA impacts insulin affordability with the backdrop of the 100-year anniversary of the discovery of insulin.

A meta-analysis with data from nearly 60k patients suggests presence of metabolic syndrome was associated with a 46% increase in risk of a second stroke and a 27% increase in risk of mortality among stroke survivors when compared to their counterparts without metabolic syndrome.

An ancillary study to the INFINITE trial details the benefits of caloric restriction plus exercise versus exercise alone on aortic stiffness measured using CMRI in older adults with obesity.

With FDA clearance announced in a statement on August 3, the Ultreon Software, which combines OCT imaging with artificial intelligence, could help improve diagnosis and treatment compared to traditional imaging methods.

Using data from the National Health Interview Survey, investigators determined patients with diabetes in high deductible health plans were 28% more likely than those in traditional health plans to report cost-related medication non-adherence and this gap only widened when examining insulin users.

Announced on July 28, insulin glargine-yfgn (Semglee) becomes the first interchange biosimilar insulin product to receive approval in the FDA's history and is expected to be available by the end of the year.

Despite the notion they are unsafe, a pair of studies demonstrate there were no significant differences in outcomes among heart transplant recipients receiving a donor heart based on a history of illicit drug use or overdose.

A retrospective cohort study with data from nearly 4 million patients with hypertension from the US, Germany, and South Korea found ACEs and ARBs provide similar efficacy for prevention of cardiovascular events, but ACEs were associated with a greater risk of adverse events.

An analysis of a subset of patients from the STAMPEDE trial provides new evidence detailing the quality of life improvements associated with undergoing bariatric surgery in patients with uncontrolled type 2 diabetes.